JP2004527535A - 抗発作発生剤および／または抗癲癇誘発剤としてのピリミジン化合物 - Google Patents

抗発作発生剤および／または抗癲癇誘発剤としてのピリミジン化合物 Download PDF

Info

Publication number
JP2004527535A
JP2004527535A JP2002581407A JP2002581407A JP2004527535A JP 2004527535 A JP2004527535 A JP 2004527535A JP 2002581407 A JP2002581407 A JP 2002581407A JP 2002581407 A JP2002581407 A JP 2002581407A JP 2004527535 A JP2004527535 A JP 2004527535A
Authority
JP
Japan
Prior art keywords
compound
subject
pharmaceutically acceptable
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002581407A
Other languages
English (en)
Japanese (ja)
Inventor
ドナルド エフ． ウィーバー
ブヘンドワ ムソール ギラン
ジョン アール． カーラン
キャサリン ジョンズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University at Kingston
Original Assignee
Queens University at Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queens University at Kingston filed Critical Queens University at Kingston
Publication of JP2004527535A publication Critical patent/JP2004527535A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2002581407A 2001-04-11 2002-04-11 抗発作発生剤および／または抗癲癇誘発剤としてのピリミジン化合物 Withdrawn JP2004527535A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28298701P 2001-04-11 2001-04-11
US28594001P 2001-04-23 2001-04-23
US31074801P 2001-08-07 2001-08-07
US9993402A 2002-03-13 2002-03-13
PCT/CA2002/000512 WO2002083651A2 (fr) 2001-04-11 2002-04-11 Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou anti-epileptiques

Publications (1)

Publication Number Publication Date
JP2004527535A true JP2004527535A (ja) 2004-09-09

Family

ID=27493095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002581407A Withdrawn JP2004527535A (ja) 2001-04-11 2002-04-11 抗発作発生剤および／または抗癲癇誘発剤としてのピリミジン化合物

Country Status (4)

Country Link
EP (1) EP1385831A2 (fr)
JP (1) JP2004527535A (fr)
CA (1) CA2444148A1 (fr)
WO (1) WO2002083651A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502967A (ja) * 2014-01-03 2017-01-26 ユニバーシティ オブ サザン カリフォルニア ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003249812A1 (en) * 2002-07-18 2004-02-09 Queen's University At Kingston Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
AU2004234110A1 (en) * 2003-04-25 2004-11-11 Rega Foundation Heterocyclic compounds for use in the treatment of viral infections
BRPI0508310A (pt) 2004-03-02 2007-07-24 Hoffmann La Roche derivados de 4-(sulfanil-pirimidin-4-ilmetil)-morfolina e compostos relacionados como ligandos do receptor gaba, para o tratamento de ansiedade, depressão e epilepsia
JP5291124B2 (ja) * 2008-01-30 2013-09-18 シン・プーン・ファーマシューティカル・カンパニー・リミテッド 新規なキナゾリン−２，４−ジオン誘導体、及びこれを含有する脳神経系疾患の予防及び治療用医薬組成物
DE102008030091B4 (de) 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
WO2014107622A1 (fr) 2013-01-07 2014-07-10 University Of Southern California Inhibiteurs de la désoxyuridine triphosphatase
CN103788095A (zh) * 2014-01-20 2014-05-14 四川大学华西医院 2,4(1h,3h)-嘧啶二酮衍生物及其制备方法
CN104788389A (zh) * 2015-04-09 2015-07-22 新乡市创新生物科技有限公司 一种5-溴尿嘧啶的制备方法
WO2017006271A1 (fr) 2015-07-08 2017-01-12 University Of Southern California Inhibiteurs de désoxyuridine triphosphatase contenant une liaison sulfonyle aminée
EP3319939A1 (fr) 2015-07-08 2018-05-16 CV6 Therapeutics (NI) Limited Hydantoïne contenant des inhibiteurs de la désoxyuridine triphosphatase
US10544105B2 (en) 2015-07-08 2020-01-28 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
US10577321B2 (en) 2015-07-08 2020-03-03 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2017123823A1 (fr) * 2016-01-12 2017-07-20 Bioelectron Technology Corporation Inhibiteurs de sulfure:quinone oxydoréductase alkyle, acyle, urée, et aza-uracile
US11168059B2 (en) 2016-11-23 2021-11-09 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
US10829457B2 (en) 2016-11-23 2020-11-10 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018098207A1 (fr) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoïne contenant des inhibiteurs de la désoxyuridine triphosphatase
US11174271B2 (en) 2016-11-23 2021-11-16 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
WO2018098206A1 (fr) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoïne contenant des inhibiteurs de la désoxyuridine triphosphatase
US11247984B2 (en) 2017-01-05 2022-02-15 Cv6 Therapeutics (Ni) Limited Uracil containing compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0425669B1 (fr) * 1988-07-18 1995-01-25 Yamasa Shoyu Kabushiki Kaisha also trading as Yamasa Corporation 1-amino-5-halogeno-uraciles, procede de preparation de ces composes, et agents depresseurs du systeme nerveux central les contenant en tant qu'ingredients actifs
DE4300912A1 (de) * 1993-01-15 1994-07-21 Merck Patent Gmbh Chinazolinderivate
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
PT1171137E (pt) * 1999-02-23 2008-03-17 Univ California Utilização de triacetiluridina para o tratamento de perturbações mitocondriais
WO2001051490A1 (fr) * 2000-01-14 2001-07-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Analogues nucleosidiques de methanocarba cycloalkyle

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502967A (ja) * 2014-01-03 2017-01-26 ユニバーシティ オブ サザン カリフォルニア ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤

Also Published As

Publication number Publication date
WO2002083651A2 (fr) 2002-10-24
WO2002083651A3 (fr) 2002-12-19
EP1385831A2 (fr) 2004-02-04
CA2444148A1 (fr) 2002-10-24

Similar Documents

Publication Publication Date Title
US7268164B2 (en) Anti-epileptogenic agents
JP2004527535A (ja) 抗発作発生剤および／または抗癲癇誘発剤としてのピリミジン化合物
US7501429B2 (en) Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
ES2378776T3 (es) Derivado de ácido aminocarboxílico y uso medicinal del mismo
US20060014752A1 (en) Heterocyclic anti-epileptogenic agents and methods of use thereof
EP2468732B1 (fr) 1H-quinazoline-2,4-diones
JP2007302678A (ja) 抗癲癇誘発剤
KR20200022480A (ko) 모발 성장을 조절하기 위한 조성물 및 방법
EP3596079B1 (fr) Dérivés de pyrazolo[1,5-a]pyrimidine à substitution aryle pharmacologiquement actifs
CN103391932B (zh) 用于抑制pask的杂环化合物
WO2006070292A2 (fr) Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou agents anti-epileptogeniques
EP2382206B1 (fr) Composés et procédés pour le traitement de la douleur et d'autres maladies
JPH11509847A (ja) ヘテロ環式化合物、それらの調製及び使用
EP3564256A1 (fr) Modulateurs du récepteur nmda
AU2002249037A1 (en) Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
JP4176150B2 (ja) グルタミン酸放出阻害剤および新規化合物
CA2521212A1 (fr) Agents anti-epileptogenes
AU2004242564A1 (en) Anti-epileptogenic agents
CN101466668A (zh) 作为肾素抑制剂的吡咯烷化合物
NZ759233B2 (en) Compositions and methods for modulating hair growth
AU2002242534A1 (en) Anti-epileptogenic agents

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050408

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20050502

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080904

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080905